These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 19507328

  • 1. Schedules of controlled substances: placement of lacosamide into schedule V. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2009 May 21; 74(97):23789-90. PubMed ID: 19507328
    [Abstract] [Full Text] [Related]

  • 2. Schedules of controlled substances: placement of lisdexamfetamine into schedule II. Final rule.
    Drug Enforcement Administration, Department of Justice.
    Fed Regist; 2007 May 03; 72(85):24532-4. PubMed ID: 17520775
    [Abstract] [Full Text] [Related]

  • 3. Schedules of controlled substances: placement of Zopiclone into schedule IV. Final rule.
    Drug Enforcement Administration, Department of Justice.
    Fed Regist; 2005 Apr 04; 70(63):16935-7. PubMed ID: 15806735
    [Abstract] [Full Text] [Related]

  • 4. Schedules of controlled substances: placement of 5-methoxy-N,N-dimethyltryptamine into Schedule I of the Controlled Substances Act. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2010 Dec 20; 75(243):79296-300. PubMed ID: 21171485
    [Abstract] [Full Text] [Related]

  • 5. Schedules of controlled substances: placement of tapentadol into schedule II. Final rule.
    Drug Enforcement Administration, Department of Justice.
    Fed Regist; 2009 May 21; 74(97):23790-3. PubMed ID: 19507329
    [Abstract] [Full Text] [Related]

  • 6. Schedules of controlled substances: placement of pregabalin into schedule V. Final rule.
    Drug Enforcement Administration, Department of Justice.
    Fed Regist; 2005 Jul 28; 70(144):43633-5. PubMed ID: 16050051
    [Abstract] [Full Text] [Related]

  • 7. Schedule of controlled substances: placement of dichloralphenazone into Schedule IV. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2001 Aug 16; 66(159):42943-4. PubMed ID: 11794309
    [Abstract] [Full Text] [Related]

  • 8. Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2004 Sep 29; 69(188):58950-3. PubMed ID: 15455477
    [Abstract] [Full Text] [Related]

  • 9. Schedule of controlled substances; placement of fospropofol into schedule IV. Final rule.
    Drug Enforcement Administration, Department of Justice.
    Fed Regist; 2009 Oct 06; 74(192):51234-6. PubMed ID: 19877370
    [Abstract] [Full Text] [Related]

  • 10. Schedules of controlled substances: temporary placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into Schedule I. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2003 Apr 04; 68(65):16427-30. PubMed ID: 12678045
    [Abstract] [Full Text] [Related]

  • 11. Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2004 Mar 18; 69(53):12794-7. PubMed ID: 15029891
    [Abstract] [Full Text] [Related]

  • 12. Schedules of controlled substances: rescheduling of buprenorphine from schedule V to schedule III. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2002 Oct 07; 67(194):62354-70. PubMed ID: 12369590
    [Abstract] [Full Text] [Related]

  • 13. Schedules of controlled substances: rescheduling of the Food and Drug Administration approved product containing synthetic dronabinol [(-) - [DELTA] less than 9 greater than - (trans)-tetrahydrocannabinol] in sesame oil and encapsulated in soft gelatin capsules from schedule II to schedule III. Department of Justice (DOJ), Drug Enforcement Administration (DEA). Final rule.
    Fed Regist; 1999 Jul 02; 64(127):35928-30. PubMed ID: 10558581
    [Abstract] [Full Text] [Related]

  • 14. Schedules of controlled substances: placement of perampanel into Schedule III. Final rule.
    Drug Enforcement Administration, Department of Justice.
    Fed Regist; 2013 Dec 02; 78(231):72013-6. PubMed ID: 24294637
    [Abstract] [Full Text] [Related]

  • 15. Schedules of controlled substances: temporary placement of three synthetic cannabinoids into Schedule I. Final order.
    Drug Enforcement Administration, Department of Justice.
    Fed Regist; 2013 May 16; 78(95):28735-9. PubMed ID: 23678676
    [Abstract] [Full Text] [Related]

  • 16. Schedules of controlled substances: placement of suvorexant into Schedule IV. Final rule.
    Drug Enforcement Administration, Department of Justice.
    Fed Regist; 2014 Aug 28; 79(167):51243-7. PubMed ID: 25167596
    [Abstract] [Full Text] [Related]

  • 17. Schedules of controlled substances: placement of ezogabine into Schedule V. Final rule.
    Drug Enforcement Administration, Department of Justice.
    Fed Regist; 2011 Dec 15; 76(241):77895-99. PubMed ID: 22175093
    [Abstract] [Full Text] [Related]

  • 18. Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I. Final Order.
    Drug Enforcement Administration, Department of Justice.
    Fed Regist; 2011 Oct 21; 76(204):65371-5. PubMed ID: 22016903
    [Abstract] [Full Text] [Related]

  • 19. Schedule of controlled substances: placement of tramadol into schedule IV. Final rule.
    Drug Enforcement Administration, Department of Justice.
    Fed Regist; 2014 Jul 02; 79(127):37623-30. PubMed ID: 25016619
    [Abstract] [Full Text] [Related]

  • 20. Classification of three steroids as schedule III anabolic steroids under the Controlled Substances Act. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2009 Dec 04; 74(232):63603-10. PubMed ID: 20169675
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.